1314801-63-2
Chemical Structure
AT 1001
- CAS No.: 1314801-63-2
- Formula:C15H21BrN2
- Molecular Weight:309.24
IUPAC Name: (1R,3r,5S)-N-(2-bromophenyl)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine
InChIKey: UZJWAFOJOSGEKL-CLLJXQQHSA-N
SMILES: BrC(C=CC=C1)=C1N[C@H]2C[C@@H]3N(C)[C@@H](CCC3)C2
Biological Activity:
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AT 1001 | 99.94% | AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a Ki value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Toll L, et al. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology. 2012;37(6):1367-1376. [Content Brief]
- [2]. Paterson BM, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007;26(5):757-766. [Content Brief]
- [3]. Cippitelli A, et al. AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015;172(7):1834-1845. [Content Brief]
Keywords
